在肠道内细菌的作用下,狄戈辛能够代谢成内酯环被还原的无心脏活性的降解产物(DRP)。约有十分之一的病人,DRP在尿液内狄戈辛和所有代谢产物的总量中所占比例可达35～40％以上。因此临床往往需要增大用药剂量方能获得满意疗效。抗生素治疗会使肠道内细菌受到抑制,DRP生成减少,这时血药浓度升高,血清狄戈辛水平甚至可增高100％。新近发展的浓胶丸剂,据认为具有比片剂高得多的生物利用度和溶出速率。本文根据DRP经尿排出量与制剂生物利用度成反比的原理,以0.4mg的单剂量给予浓胶丸和标准片剂,比较二种制剂在给药 Under the action of intestinal bacteria, Digoxin can metabolize the reduced lactose-free degradation product (DRP) of the lactone ring. About a tenth of patients, DRP accounts for more than 35-40% of total urinary Digoxin and all metabolites. Therefore, it is often necessary to increase the dose of clinical trials to obtain satisfactory results. Antibiotic treatment can inhibit the gut bacteria, DRP reduced production, when the blood concentration, serum Digoxin levels can even be increased by 100%. Newly developed concretions are believed to have much higher bioavailability and dissolution rates than tablets. In this paper, according to DRP transurethral discharge and preparation bioavailability is inversely proportional to the principle of a single dose of 0.4mg to give concentrated capsules and standard tablets, compared two formulations in the administration